Viviana Alejandra Ruiz Pozo

Ms. Viviana Alejandra Ruiz Pozo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
VPViviana Alejandra Ruiz Pozo
Viviana Alejandra Ruiz Pozo
RTRafael Tamayo-Trujillo
Rafael Tamayo-Trujillo
SCSantiago Cadena-Ullauri
Santiago Cadena-Ullauri
Evelyn Frias-ToralEvelyn Frias-Toral
Evelyn Frias-Toral
PGPatricia Guevara
Patricia Guevara
AZAna Karina Zambrano
Ana Karina Zambrano
Parkinson’s disease (PD) is a degenerative condition resulting from the loss of dopaminergic neurons. This neuronal loss leads to motor and non-motor neurological symptoms. Most PD cases are idiopathic, and no cure is available. Recently, it has been proposed that insulin resistance (IR) could be a central factor in PD development. IR has been associated with PD neuropathological features like α-synuclein aggregation, dopaminergic neuronal loss, neuroinflammation, mitochondrial dysfunction, and autophagy. These features are related to impaired neurological metabolism, neuronal death, and the aggravation of PD symptoms. Moreover, pharmacological options that involve insulin signaling improvement and dopaminergic and non-dopaminergic strategies have been under development. These drugs could prevent the metabolic pathways involved in neuronal damage. All these approaches could improve PD outcomes. Also, new biomarker identification may allow for an earlier PD diagnosis in high-risk individuals. This review describes the main pathways implicated in PD development involving IR. Also, it presents several therapeutic options that are directed at insulin signaling improvement and could be used in PD treatment. The understanding of IR molecular mechanisms involved in neurodegenerative development could enhance PD therapeutic options and diagnosis.

Verified
Journal Article
Open access
PDF file
PGPatricia Guevara
Patricia Guevara
SCSantiago Cadena-Ullauri
Santiago Cadena-Ullauri
EPElius Paz-Cruz
Elius Paz-Cruz
VPViviana Alejandra Ruiz Pozo
Viviana Alejandra Ruiz Pozo
RTRafael Tamayo-Trujillo
Rafael Tamayo-Trujillo
AZAna Karina Zambrano
Ana Karina Zambrano
Hematologic malignancies (HMs), including leukemia, lymphoma, and multiple myeloma, involve the uncontrolled proliferation of abnormal blood cells, posing significant clinical challenges due to their heterogeneity and varied treatment responses. Despite recent advancements in therapies that have improved survival rates, particularly in chronic lymphocytic leukemia and acute lymphoblastic leukemia, treatments like chemotherapy and stem cell transplantation often disrupt gut microbiota, which can negatively impact treatment outcomes and increase infection risks. This review explores the complex, bidirectional interactions between gut microbiota and cancer treatments in patients with HMs. Gut microbiota can influence drug metabolism through mechanisms such as the production of enzymes like bacterial β-glucuronidases, which can alter drug efficacy and toxicity. Moreover, microbial metabolites like short-chain fatty acids can modulate the host immune response, enhancing treatment effectiveness. However, therapy often reduces the diversity of beneficial bacteria, such as Bifidobacterium and Faecalibacterium, while increasing pathogenic bacteria like Enterococcus and Escherichia coli. These findings highlight the critical need to preserve microbiota diversity during treatment. Future research should focus on personalized microbiome-based therapies, including probiotics, prebiotics, and fecal microbiota transplantation, to improve outcomes and quality of life for patients with hematologic malignancies.

Verified
Journal Article
Open access
PDF file
PGPatricia Guevara
Patricia Guevara
RTRafael Tamayo-Trujillo
Rafael Tamayo-Trujillo
VPViviana Alejandra Ruiz Pozo
Viviana Alejandra Ruiz Pozo
SCSantiago Cadena-Ullauri
Santiago Cadena-Ullauri
EPElius Paz-Cruz
Elius Paz-Cruz
AZAna Karina Zambrano
Ana Karina Zambrano
Autism spectrum disorder (ASD) is a neurodevelopmental condition frequently associated with gastrointestinal symptoms, gut dysbiosis, and metabolic dysfunctions such as insulin resistance (IR). Recent evidence suggests that the gut microbiota may influence both metabolic and neurological processes through the gut–brain–metabolic axis. This review explores the molecular mechanisms linking dysbiosis, IR, and ASD, focusing on pathways such as TLR/NF-κB activation, PI3K/Akt/mTOR disruption, and the action of microbial metabolites, like short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and γ-aminobutyric acid (GABA). We discuss how dysbiosis may contribute to increased intestinal permeability, systemic inflammation, and neuroimmune activation, ultimately affecting brain development and behavior. Common microbial alterations in ASD and IR—including increased Clostridium, Desulfovibrio, and Alistipes, and reduced Bifidobacterium and butyrate-producing genera—suggest a shared pathophysiology. We also highlight potential therapeutic strategies, such as microbiota modulation, insulin-like growth factor 1 (IGF-1) treatment, and dietary interventions. Understanding these interconnected mechanisms may support the development of microbiota-targeted approaches for individuals with ASD metabolic comorbidities.

13 June 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
AZAna Karina Zambrano
Ana Karina Zambrano
SCSantiago Cadena-Ullauri
Santiago Cadena-Ullauri
PGPatricia Guevara
Patricia Guevara
Evelyn Frias-ToralEvelyn Frias-Toral
Evelyn Frias-Toral
VPViviana Alejandra Ruiz Pozo
Viviana Alejandra Ruiz Pozo
DSDaniel Simancas-Racines
Daniel Simancas-Racines
The very-low-calorie KD (VLCKD) is characterized by a caloric intake of under 800 kcal/day divided into less than 50 g/day of carbohydrate (13%) and 1 to 1.5 g of protein/kg of body weight (44%) and 43% of fat. This low carbohydrate intake changes the energy source from glucose to ketone bodies. Moreover, clinical trials have consistently shown a beneficial effect of VLCKD in several diseases, such as heart failure, schizophrenia, multiple sclerosis, Parkinson’s, and obesity, among others. The gut microbiota has been associated with the metabolic conditions of a person and is regulated by diet interactions; furthermore, it has been shown that the microbiota has a role in body weight homeostasis by regulating metabolism, appetite, and energy. Currently, there is increasing evidence of an association between gut microbiota dysbiosis and the pathophysiology of obesity. In addition, the molecular pathways, the role of metabolites, and how microbiota modulation could be beneficial remain unclear, and more research is needed. The objective of the present article is to contribute with an overview of the impact that VLCKD has on the intestinal microbiota composition of individuals with obesity through a literature review describing the latest research regarding the topic and highlighting which bacteria phyla are associated with obesity and VLCKD.

1 October 2023 in Cardiology Research
Verified
Journal Article
Open access
PDF file
EPElius Paz-Cruz
Elius Paz-Cruz
VPViviana Alejandra Ruiz Pozo
Viviana Alejandra Ruiz Pozo
SCSantiago Cadena-Ullauri
Santiago Cadena-Ullauri
PGPatricia Guevara
Patricia Guevara
RTRafael Tamayo-Trujillo
Rafael Tamayo-Trujillo
AZAna Karina Zambrano
Ana Karina Zambrano
Associations of MYPN, TTN, SCN5A, MYO6 and ELN Mutations With Arrhythmias and Subsequent Sudden Cardiac Death: A Case Report of an Ecuadorian Individual

20 December 2023 in Heliyon
Verified
Journal Article
Open access
EPElius Paz-Cruz
Elius Paz-Cruz
SCSantiago Cadena-Ullauri
Santiago Cadena-Ullauri
PGPatricia Guevara
Patricia Guevara
VPViviana Alejandra Ruiz Pozo
Viviana Alejandra Ruiz Pozo
RTRafael Tamayo-Trujillo
Rafael Tamayo-Trujillo
AZAna Karina Zambrano
Ana Karina Zambrano
The purpose of this study is to describe the genetic variants present in the Ecuadorian population and the incidence and mortality patterns of thyroid cancer in Ecuador from 2016 to 2021. The present research constitutes a nationwide cross-sectional study encompassing all reported cases of thyroid cancer (C-73) in Ecuador from 2016 to 2021. Incidence rates were calculated based on the annual population at risk, considering factors such as ethnicity, sex, age group, and the geographic location of the incidence. All data was collected from the Hospital Discharge Statistics and the Statistical Registry of General Deaths Databases. Between 2016 and 2021, a total of 20,297 hospital admissions and 921 deaths attributed to thyroid cancer were reported in Ecuador. The incidence of thyroid cancer remained relatively stable from 2016 to 2019. However, there was a notable decrease in 2020, followed by an increase in 2021. Notably, thyroid cancer prevalence rates were found to be higher in highlands regions. Moreover, two genetic variants, the BRAFV600E and KITL678F, have been identified in the Ecuadorian population. It is noteworthy that women exhibited a higher susceptibility to thyroid cancer, being five times more likely than men to develop this condition. Ecuador exhibits one of the highest global incidences of thyroid cancer. Consequently, describing the genetic variants and epidemiological characteristics of thyroid cancer is imperative for enhancing healthcare access and formulating evidence-based public health policies. This research contributes towards a comprehensive understanding of thyroid cancer in the Ecuadorian context, aiming to improve targeted interventions and health outcomes.